 Cristos Ifantides
Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cataract | 8 | 2023 | 221 | 2.950 |
Why?
| | Cataract Extraction | 4 | 2023 | 105 | 2.280 |
Why?
| | Lenses, Intraocular | 4 | 2022 | 45 | 1.530 |
Why?
| | Ophthalmology | 2 | 2023 | 104 | 1.430 |
Why?
| | Capsulorhexis | 2 | 2022 | 8 | 0.960 |
Why?
| | Dry Eye Syndromes | 5 | 2024 | 54 | 0.920 |
Why?
| | Posterior Capsulotomy | 1 | 2022 | 7 | 0.790 |
Why?
| | Lens Capsule, Crystalline | 1 | 2022 | 13 | 0.780 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 82 | 0.760 |
Why?
| | Weapons | 1 | 2021 | 9 | 0.690 |
Why?
| | Lens Subluxation | 1 | 2021 | 3 | 0.690 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.690 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.690 |
Why?
| | Eye Injuries | 1 | 2021 | 53 | 0.660 |
Why?
| | Granuloma, Foreign-Body | 1 | 2020 | 10 | 0.640 |
Why?
| | Tattooing | 1 | 2020 | 12 | 0.640 |
Why?
| | Language | 1 | 2023 | 305 | 0.630 |
Why?
| | Hepatitis C | 1 | 2022 | 246 | 0.630 |
Why?
| | Health Status Disparities | 1 | 2023 | 295 | 0.630 |
Why?
| | Macular Edema | 1 | 2020 | 46 | 0.610 |
Why?
| | Uveitis | 1 | 2020 | 146 | 0.570 |
Why?
| | Glaucoma, Open-Angle | 2 | 2021 | 104 | 0.570 |
Why?
| | Healthcare Disparities | 1 | 2023 | 659 | 0.500 |
Why?
| | Nocardia | 1 | 2015 | 4 | 0.460 |
Why?
| | Nocardia Infections | 1 | 2015 | 10 | 0.460 |
Why?
| | Eye Infections, Bacterial | 1 | 2015 | 39 | 0.450 |
Why?
| | Internship and Residency | 1 | 2023 | 1187 | 0.390 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 10 | 0.360 |
Why?
| | Surgical Wound Infection | 1 | 2015 | 313 | 0.360 |
Why?
| | Phacoemulsification | 2 | 2023 | 120 | 0.350 |
Why?
| | Lens Implantation, Intraocular | 2 | 2022 | 67 | 0.350 |
Why?
| | Retrospective Studies | 8 | 2023 | 15909 | 0.300 |
Why?
| | Trabeculectomy | 2 | 2021 | 74 | 0.270 |
Why?
| | Humans | 23 | 2024 | 138651 | 0.220 |
Why?
| | Refraction, Ocular | 2 | 2022 | 43 | 0.210 |
Why?
| | Masks | 1 | 2023 | 66 | 0.200 |
Why?
| | Corneal Injuries | 1 | 2023 | 46 | 0.190 |
Why?
| | Anesthetics, Local | 1 | 2023 | 98 | 0.190 |
Why?
| | Photorefractive Keratectomy | 1 | 2022 | 20 | 0.190 |
Why?
| | Keratomileusis, Laser In Situ | 1 | 2022 | 20 | 0.190 |
Why?
| | Hemorrhagic Fever, Ebola | 1 | 2022 | 78 | 0.180 |
Why?
| | Glaucoma Drainage Implants | 1 | 2022 | 45 | 0.180 |
Why?
| | United States | 4 | 2024 | 14938 | 0.180 |
Why?
| | Alanine Transaminase | 1 | 2022 | 147 | 0.180 |
Why?
| | Postoperative Complications | 4 | 2022 | 2722 | 0.180 |
Why?
| | Safety-net Providers | 1 | 2023 | 118 | 0.180 |
Why?
| | Intraoperative Complications | 1 | 2022 | 148 | 0.170 |
Why?
| | Dissent and Disputes | 1 | 2021 | 20 | 0.170 |
Why?
| | Aberrometry | 1 | 2020 | 9 | 0.170 |
Why?
| | Visual Acuity | 2 | 2022 | 428 | 0.170 |
Why?
| | Republic of Korea | 1 | 2020 | 41 | 0.170 |
Why?
| | Hepacivirus | 1 | 2022 | 238 | 0.170 |
Why?
| | Crowding | 1 | 2021 | 36 | 0.170 |
Why?
| | Optics and Photonics | 1 | 2020 | 42 | 0.170 |
Why?
| | Myopia | 1 | 2020 | 55 | 0.160 |
Why?
| | Adalimumab | 1 | 2020 | 53 | 0.160 |
Why?
| | Foreign-Body Reaction | 1 | 2020 | 32 | 0.160 |
Why?
| | Benchmarking | 1 | 2020 | 187 | 0.150 |
Why?
| | Glaucoma | 1 | 2022 | 241 | 0.150 |
Why?
| | Steroids | 1 | 2020 | 163 | 0.150 |
Why?
| | Health Surveys | 1 | 2021 | 504 | 0.150 |
Why?
| | Education, Medical, Graduate | 1 | 2023 | 496 | 0.150 |
Why?
| | Ambulatory Care | 1 | 2023 | 575 | 0.140 |
Why?
| | Glucocorticoids | 1 | 2022 | 528 | 0.140 |
Why?
| | Intraocular Pressure | 2 | 2022 | 313 | 0.140 |
Why?
| | Curriculum | 1 | 2023 | 1009 | 0.120 |
Why?
| | Biopsy | 1 | 2020 | 1072 | 0.120 |
Why?
| | Surgical Stomas | 1 | 2015 | 7 | 0.120 |
Why?
| | Clinical Competence | 1 | 2023 | 1149 | 0.120 |
Why?
| | Amikacin | 1 | 2015 | 25 | 0.110 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2015 | 42 | 0.110 |
Why?
| | Tomography, Optical Coherence | 1 | 2015 | 234 | 0.100 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 1032 | 0.090 |
Why?
| | Cornea | 2 | 2023 | 150 | 0.090 |
Why?
| | Sports Equipment | 1 | 2011 | 9 | 0.090 |
Why?
| | Risk Factors | 2 | 2022 | 10252 | 0.090 |
Why?
| | Staphylococcal Skin Infections | 1 | 2011 | 34 | 0.080 |
Why?
| | Equipment Contamination | 1 | 2011 | 71 | 0.080 |
Why?
| | Receptors, CCR2 | 1 | 2009 | 39 | 0.080 |
Why?
| | Shear Strength | 1 | 2009 | 68 | 0.080 |
Why?
| | Transplants | 1 | 2009 | 38 | 0.080 |
Why?
| | Tunica Intima | 1 | 2009 | 76 | 0.080 |
Why?
| | Veins | 1 | 2009 | 66 | 0.080 |
Why?
| | Community-Acquired Infections | 1 | 2011 | 173 | 0.070 |
Why?
| | Receptor, Platelet-Derived Growth Factor beta | 1 | 2008 | 29 | 0.070 |
Why?
| | Prospective Studies | 1 | 2020 | 7554 | 0.070 |
Why?
| | Adult | 5 | 2024 | 38201 | 0.070 |
Why?
| | Graft Occlusion, Vascular | 1 | 2008 | 39 | 0.070 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2011 | 236 | 0.070 |
Why?
| | Male | 7 | 2023 | 68260 | 0.070 |
Why?
| | Immediate-Early Proteins | 1 | 2007 | 49 | 0.070 |
Why?
| | Jugular Veins | 1 | 2007 | 42 | 0.060 |
Why?
| | Blood Vessels | 1 | 2008 | 180 | 0.060 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2008 | 259 | 0.060 |
Why?
| | C-Reactive Protein | 1 | 2008 | 415 | 0.060 |
Why?
| | Incidence | 2 | 2022 | 2747 | 0.060 |
Why?
| | Prevalence | 2 | 2022 | 2727 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2007 | 385 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1818 | 0.060 |
Why?
| | Graft Survival | 1 | 2007 | 491 | 0.050 |
Why?
| | Transforming Growth Factor beta | 1 | 2007 | 488 | 0.050 |
Why?
| | Tears | 1 | 2023 | 28 | 0.050 |
Why?
| | Loteprednol Etabonate | 1 | 2022 | 5 | 0.050 |
Why?
| | Lubricant Eye Drops | 1 | 2022 | 9 | 0.050 |
Why?
| | Meibomian Glands | 1 | 2022 | 18 | 0.050 |
Why?
| | Tobramycin | 1 | 2022 | 52 | 0.050 |
Why?
| | Lasers, Excimer | 1 | 2022 | 29 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2022 | 5112 | 0.050 |
Why?
| | Communication Barriers | 1 | 2023 | 115 | 0.050 |
Why?
| | Middle Aged | 3 | 2023 | 33604 | 0.050 |
Why?
| | Fibroblasts | 1 | 2007 | 1003 | 0.050 |
Why?
| | Mitomycin | 1 | 2021 | 33 | 0.040 |
Why?
| | Cyclosporine | 1 | 2022 | 265 | 0.040 |
Why?
| | Analgesics | 1 | 2023 | 225 | 0.040 |
Why?
| | Prosthesis Implantation | 1 | 2022 | 156 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 67 | 0.040 |
Why?
| | Meta-Analysis as Topic | 1 | 2021 | 184 | 0.040 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 347 | 0.040 |
Why?
| | Pain, Postoperative | 1 | 2023 | 309 | 0.040 |
Why?
| | India | 1 | 2020 | 203 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5520 | 0.040 |
Why?
| | Global Health | 1 | 2022 | 383 | 0.040 |
Why?
| | Cell Movement | 3 | 2009 | 969 | 0.040 |
Why?
| | Disease Outbreaks | 1 | 2022 | 416 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2022 | 496 | 0.040 |
Why?
| | Hospitals | 1 | 2023 | 695 | 0.040 |
Why?
| | Aged | 3 | 2023 | 24024 | 0.030 |
Why?
| | Female | 5 | 2024 | 73763 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2022 | 10923 | 0.030 |
Why?
| | Rabbits | 2 | 2009 | 747 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1518 | 0.030 |
Why?
| | Signal Transduction | 1 | 2009 | 5086 | 0.030 |
Why?
| | Research Design | 1 | 2021 | 1118 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2022 | 3523 | 0.030 |
Why?
| | Adolescent | 2 | 2023 | 21564 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2020 | 1092 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 5803 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2009 | 116 | 0.020 |
Why?
| | Hyperplasia | 1 | 2009 | 176 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2020 | 7677 | 0.020 |
Why?
| | Elastin | 1 | 2008 | 79 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2008 | 154 | 0.020 |
Why?
| | Leukocytes | 1 | 2009 | 307 | 0.020 |
Why?
| | Gene Deletion | 1 | 2009 | 388 | 0.020 |
Why?
| | Chemotaxis | 1 | 2008 | 133 | 0.020 |
Why?
| | Child, Preschool | 1 | 2022 | 11158 | 0.020 |
Why?
| | Transplantation, Autologous | 1 | 2008 | 275 | 0.020 |
Why?
| | Connective Tissue Growth Factor | 1 | 2007 | 26 | 0.020 |
Why?
| | Young Adult | 1 | 2023 | 13305 | 0.020 |
Why?
| | Blotting, Western | 1 | 2008 | 1230 | 0.010 |
Why?
| | Cell Survival | 1 | 2008 | 1123 | 0.010 |
Why?
| | Hemodynamics | 1 | 2009 | 1093 | 0.010 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2008 | 748 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2008 | 1731 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 2049 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1760 | 0.010 |
Why?
| | Child | 1 | 2022 | 21921 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2480 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2008 | 4181 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2009 | 2590 | 0.010 |
Why?
| | Phenotype | 1 | 2008 | 3139 | 0.010 |
Why?
| | Animals | 2 | 2009 | 37217 | 0.010 |
Why?
| | Mice | 1 | 2009 | 17814 | 0.010 |
Why?
|
|
Ifantides's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|